NX-2127, developed by Nurix Therapeutics, is an oral BTK degrader currently under evaluation in Phase 1 clinical trials for B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) [15]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.